Stories
AIIMS Extends Ban on Pentagon Labs Over Repeated IV Fluid Contamination
- •AIIMS New Delhi has extended the debarment of Pentagon Labs Ltd until September 26, 2027, due to persistent complaints of contaminated intravenous fluids.
- •The complaints include visible particulate matter and fungal contamination in several IV fluid products, despite earlier warnings to the company.
- •Pentagon Labs had challenged an initial two-year debarment from 2025, leading to a reconsideration process by AIIMS and the Delhi High Court.
- •During reconsideration, AIIMS received fresh complaints about other IV-fluid products, prompting a show-cause notice and personal hearing.
- •AIIMS rejected Pentagon's argument that contamination could be due to logistics, stating the company had previously assured improved quality checks.
Key Questions Answered
AIIMS extended the two-year debarment of Pentagon Labs Ltd due to persistent complaints regarding visible contamination, including particulate matter and fungal growth, in its supplied intravenous fluids. Despite prior warnings and reconsideration proceedings, the institute continued to receive fresh quality complaints across multiple IV fluid products.
The debarment of Pentagon Labs Ltd from AIIMS tenders and contracts will remain in force until September 26, 2027, according to an AIIMS order issued on September 22.
During a personal hearing on August 17, 2026, Pentagon Labs acknowledged the complaints but argued that the contamination might have resulted from logistics-related issues. The company also pointed to bottle warning labels advising users to check for leaks, particulate matter, or fungal contamination before use, an argument that AIIMS rejected.
